CJC-1295

The earlier profile describes CJC-1295 with a drug affinity complex, or DAC: a chemical modification intended to support binding to albumin. A compound name on a catalogue is not enough to establish the presence of that modification. The sequence, terminal form and modification need to agree across the specification and analytical methods.

The old text mixes discussion of the peptide chain with DAC processing. Its example masses and acceptance ranges remain in the technical tables, but they are not a verified specification for every material sold under the CJC-1295 name.

The described route uses Fmoc (a temporary chemical protecting group) solid-phase peptide synthesis. Resin selection determines the terminal group, while protected side chains allow the backbone to be assembled without unwanted reactions. Coupling and deprotection monitoring help identify failures before the whole chain is cleaved.

DAC attachment adds an identity question beyond chain assembly. The manufacturing record needs evidence for the intended modification and for unmodified or incorrectly modified material. The earlier cleavage, precipitation and washing sections describe recovery of a crude product, not finished-product release.

Preparative RP-HPLC (reversed-phase high-performance liquid chromatography, which separates mixture components) separates the target from related chains and process residues. Analytical scouting establishes a useful separation before a larger column is used. The gradient schedule below is an inherited example; column loading, flow and collection windows depend on the qualified process.

Fractions need both purity and identity review before pooling. Desalting and counterion exchange reduce mobile-phase residues. Formulation, filling and freeze-drying then require their own controls for moisture, cake structure and container closure; those operations cannot repair the wrong molecular form.

Identity testing should resolve the exact form being claimed. The earlier profile combines mass spectrometry, chromatographic comparison and composition checks, then adds purity, content and physical testing. Orthogonal methods are methods based on different measurement principles.

Related-peptide analysis, size-exclusion chromatography for larger species, residual-solvent testing and microbiological methods address separate risks. The sample CoA in the appendix is a formatting example with illustrative values. It is not an observed result for CJC-1295 from any supplier.

Aggregation, oxidation and deamidation are the main stability topics in the earlier edition. Aggregation joins molecules into larger species; deamidation changes certain side chains. The study design tracks those changes rather than relying only on appearance.

Powder storage, container-closure qualification, environmental monitoring and shipping excursions belong in the stability programme. A retest date must be supported by data for the actual formulation. The earlier discussion of post-approval monitoring is a general pharmaceutical workflow, not evidence that this research material is approved.

The master batch record is the approved plan; the executed batch record shows what actually happened. Reagent lots, times, temperatures, in-process tests, yields and deviations should reconcile with the final quantity released. Corrective and preventive action, or CAPA, records how a problem was investigated and recurrence addressed.

FDA’s page current as of April 22, 2026 lists CJC-1295 among substances nominated but withdrawn. That status is not clearance for compounding or an approval for human use. The public Oath listing does not establish which CJC-1295 form or individual lot meets a project’s specification.

CJC-1295 tables retain the earlier manufacturing examples. No CJC-1295 table here validates an operating procedure, release limit or supplier result. The CJC-1295 examples have no supporting batch raw data; use them to identify document fields, not to infer measured performance.

CJC-1295 source links are retained below. These references give context for CJC-1295 manufacturing; they do not validate the numerical examples. Duplicate CJC-1295 source links retain the citation record.

1. cGMP regulations for peptide therapeutics
2. ICH Q7 guidelines for API manufacturing
3. USP harmonization standards for peptide purification
4. FDA guidance on lyophilization of parenteral products
5. ICH Q3B guidance on impurities in new drug substances
6. USP <1225> validation of compendial procedures
7. Oath Research's public lab-results archive
8. FDA quality systems guidance
9. Extractables and leachables studies per USP <1663> and <1664>
10. FDA Drug Supply Chain Security Act requirements
11. FDA cGMP requirements
12. U.S. Food and Drug Administration. (2023). Current Good Manufacturing Practice (CGMP) Regulations for Drugs. 21 CFR Parts 210 and 211. Available at: https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations
13. International Council for Harmonisation (ICH). (2023). ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Available at: https://www.ich.org/page/quality-guidelines
14. U.S. Food and Drug Administration. (2022). Guidance for Industry: Lyophilization of Parenteral Products. Center for Drug Evaluation and Research. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-lyophilization-parenteral-products
15. United States Pharmacopeia. (2024). USP Harmonization Standards for Peptide Manufacturing. USP-NF General Chapters. Available at: https://www.usp.org/harmonization-standards/pdg
16. International Council for Harmonisation (ICH). (2023). ICH Q3B(R2): Impurities in New Drug Substances. Available at: https://www.ich.org/page/quality-guidelines
17. United States Pharmacopeia. (2024). USP <1225> Validation of Compendial Procedures. Available at: https://www.usp.org/validation
18. United States Pharmacopeia. (2024). USP <1663> Assessment of Extractables Associated with Pharmaceutical Packaging/Delivery Systems and USP <1664> Assessment of Drug Product Leachables Associated with Pharmaceutical Packaging/Delivery Systems. Available at: https://www.usp.org/chemical-medicines/general-chapters
19. U.S. Food and Drug Administration. (2021). Drug Supply Chain Security Act (DSCSA). Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-supply-chain-security-act-dscsa
20. U.S. Food and Drug Administration. (2006). Guidance for Industry: Quality Systems Approach to Pharmaceutical CGMP Regulations. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-quality-systems-approach-pharmaceutical-cgmp-regulations
21. U.S. Food and Drug Administration. (2023). Facts about the Current Good Manufacturing Practices (CGMPs). Available at: https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmps